Blockonomi
Merck (MRK) Stock: Heart Drug Trial Results Push Shares Up
Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...
New Pill From Merck Could Slash Cholesterol Levels, Trials Show
The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...
BioSpace
Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025
Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...
STAT
Merck’s pill to reduce cholesterol on top of statins matches results from injectables
Merck's enlicitide pill lowered LDL cholesterol by up to 60%, matching injectables like Repatha and offering an easier option ...
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) i…
Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 ...
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial ...
BioPharma Dive
Blackstone pays Merck $700M to buy into ADC drug royalties
The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.